Mold-Tek Packaging Limited , a leader in rigid plastic packaging, has announced strong financial results for the second quarter of fiscal year 2026, demonstrating resilience and growth across multiple segments.

Key Financial Highlights

The company's performance shows a notable improvement across key financial metrics for Q2 FY2026 compared to the same period last year.

Segment-wise Performance

Pharma Packaging: A Key Growth Driver

The pharma packaging segment emerged as a standout performer, with sales growing by 45% in Q2 compared to Q1 FY2026. The company has already achieved over 50% capacity utilization in its first year of operations in this segment. Mold-Tek's reputation in In-Mold Labeling (IML) and its DMF facility with high hygiene standards have helped it gain a strong foothold in the EV tubes and stoppers market for nutraceuticals.

Food & FMCG: Steady Growth Despite Challenges

Despite a shortened season and persistent rainfall, the Food & FMCG segment, including Q-Pack, achieved a 34.89% volume growth. The company's strategic diversification into non-seasonal product categories has helped maintain consistent performance and reduce dependency on seasonal demand cycles.

Paints and Lubricants

The paints packaging segment posted a 12.34% growth, while the lubricants packaging segment experienced a 9.77% decline in volume.

Strategic Developments

1. Capacity Expansion: The company has completed capacity enhancements at Cheyyar and Panipat to meet growing demand from the Aditya Birla Group.

2. New Facility: The new Panipat facility is set to contribute from Q3 onwards, further strengthening capacity and market reach.

3. Printing Capabilities: Mold-Tek is introducing next-generation IML printing technology, which will allow for lower Minimum Order Quantities (MOQs) and reduced production costs.

4. New Customer Acquisitions: The company has secured new orders from reputed companies in both the food and pharma industries, including Veedol Corporation, Devee Agencies, Rallis India Limited, and Pharmaforce.

Management Commentary

J. Lakshmana Rao, Chairman and Managing Director, commented on the results: "Pharma Packaging will be a key driver of Mold-Tek's growth and profitability in the coming years. With multiple opportunities emerging in this space and a strong lineup of innovative products, we are confident of establishing Mold-Tek as a major player in the Pharma Packaging segment."

Future Outlook

The company's focus on innovation, quality, and customer-centric solutions positions it well for continued growth. The recent GST rate reductions on Food and FMCG ready-to-eat products have positively influenced demand across the packaging industry, which Mold-Tek is well-positioned to capitalize on with its expanded capacity and diversified product portfolio.

Mold-Tek Packaging's strong Q2 performance, coupled with its strategic initiatives and expansion plans, indicates a positive outlook for the company in the coming quarters.

Mold-Tek Packaging Limited , a leading manufacturer of plastic packaging solutions, has reported strong financial results for the first quarter, demonstrating significant growth across key metrics and segments.

Financial Highlights

• Revenue grew by 22% year-over-year
• EBITDA margin improved to 19.70% from 18.00% in the previous year
• Net profit increased by 35%
• EBITDA per kg grew by 29%

Segment Performance

Paint Segment

The paint segment emerged as a significant driver of growth, primarily supported by Aditya Birla Grasim (ABG). The company processed 5,600 tons in this segment during the quarter.

Pharma Segment

The pharma segment achieved breakeven and grew 11% compared to Q4. The company processed 190 tons in this segment and is targeting revenue of INR 35.00 crores for the current financial year, up from INR 8.00-9.00 crores last year.

Food & FMCG Segment

Despite early monsoons affecting ice cream and yogurt consumption, the Food & FMCG segment recorded 16% growth. The company processed 3,200 tons in this segment.

Lubricants Segment

The company processed 2,400 tons in the lubricants segment.

Operational Metrics

Expansion Plans

• Panipat thin wall food production is set to start in August
• Additional pharma capacity investments of INR 80.00-90.00 crores are planned
• The company expects overall volume of 43,000-45,000 tons for the full year with 12-15% value growth

Pharma Business Expansion

Multiple pharma companies, including Laurus Labs and Pulse, have approved Mold-Tek's facilities and started commercial orders. The company is expanding its pharma capacity and product range to meet growing demand.

Management Commentary

J. Lakshmana Rao, Chairman and Managing Director of Mold-Tek Packaging Limited, commented on the results during the earnings conference call: "We are very happy to inform you of an excellent performance in this quarter by Mold-Tek Packaging, where the revenues have shot up by 22%, and EBITDA margin has also shot up from 18-odd percentage last year to 19.7%. This growth was possible due to all the sectors doing very well this year."

Rao also highlighted the company's progress in the pharma segment, stating, "What is more exciting for us at Mold-Tek is the speed at which the Pharma packaging is getting adopted and approved by several major players in the pharma industry."

Future Outlook

The company remains optimistic about its growth prospects, particularly in the pharma and Food & FMCG segments. With ongoing capacity expansions and new product developments, Mold-Tek Packaging is well-positioned to capitalize on emerging opportunities in the packaging industry.

As the company continues to focus on innovation and efficiency, investors and industry observers will be watching closely to see how Mold-Tek Packaging builds on its strong start to the fiscal year.